With 62.98 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.75 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $3.38 whereas the lowest price it dropped to was $2.37. The 52-week range on MBOT shows that it touched its highest point at $2.35 and its lowest point at $0.82 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 1.45.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MBOT was up-trending over the past week, with a rise of 155.86%, but this was up by 186.87% over a month. Three-month performance surged to 215.17% while six-month performance rose 162.96%. The stock gained 97.22% in the past year, while it has gained 153.57% so far this year.
Float and Shares Shorts:
At present, 16.65 million MBOT shares are outstanding with a float of 16.55 million shares on hand for trading. On 2024-10-31, short shares totaled 0.57 million, which was 343.0 higher than short shares on 1727654400. In addition to Mr. Harel Gadot as the firm’s Co-Founder, President, CEO & Chairman, Mr. Yoseph Bornstein serves as its Co-Founder & Independent Director.
Institutional Ownership:
Through their ownership of 0.07459 of MBOT’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, MBOT reported revenue of $0.0 and operating income of -$3300000.0. The EBITDA in the recently reported quarter was -$3277000.0 and diluted EPS was -$0.2.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MBOT since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
Analysts have provided yearly estimates in a range of -$0.66 being high and -$0.66 being low. For MBOT, this leads to a yearly average estimate of -$0.66.
